Treatment with Viking Therapeutics' dual agonists resulted in mean reductions in body weight of up to 27 percent compared to semaglutide-treated animals.
List view / Grid view
Viking Therapeutics announced positive initial results from a proof-of-concept study of VK2809 in an in vivo model of glycogen storage disease Ia (GSD Ia).
27 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Model study shows how VK0214, a thyroid receptor beta agonist that regulates the expression of genes believed to be relevant to the manifestation of X-ALD...
8 December 2015 | By Victoria White
VK5211 is an orally available, non-steroidal selective androgen receptor modulator (SARM) designed to selectively stimulate muscle and bone formation with reduced activity in peripheral tissues such as skin and prostate...